Physician profile
David J Case
NPI 1922263722
$1,895.16
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $697 · 2020: $27.48 · 2021: $111 · 2022: $375 · 2023: $366 · 2024: $319.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $685.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $684.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $525.43 | 2019-2024 | Linzess, Mavyret, Viberzi |
| Pfizer INC. | $242.40 | 2019-2023 | |
| Janssen Scientific Affairs, LLC | $211.86 | 2019 | |
| Gilead Sciences, INC. | $167.93 | 2019-2021 | |
| Celgene Corporation | $109.98 | 2022-2024 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $77.30 | 2021-2024 | Plenvu, Xifaxan |
| Merck Sharp & Dohme LLC | $72.64 | 2019-2024 | Dificid |
| Lilly USA, LLC | $57.18 | 2024 | Omvoh |
| Takeda Pharmaceuticals U.S.A., INC. | $57.14 | 2022-2023 | Entyvio, Gattex |
| Janssen Biotech, INC. | $53.60 | 2023-2024 | Stelara, Simponi Aria, Simponi |
| Genzyme Corporation | $41.07 | 2023-2024 | |
| Nestle Healthcare Nutrition INC. | $33.75 | 2021-2022 | |
| Aimmune Therapeutics, INC. | $33.70 | 2024 | |
| Braintree Laboratories, INC. | $31.61 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $31.43 | 2024 | Voquezna |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $30.86 | 2024 | Resmetirom |
| Redhill Biopharma INC. | $30.28 | 2022 | |
| Shire North American Group INC | $29.77 | 2019 | |
| Shield Therapeutics INC | $20.29 | 2022 | |
| Fresenius Kabi USA, LLC | $19.15 | 2023 | Idacio |
| Intercept Pharmaceuticals, INC. | $17.79 | 2023 | Ocaliva |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Case listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.